.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,008,228

« Back to Dashboard
Patent 6,008,228 protects FORTOVASE and is included in one NDA.

Protection for FORTOVASE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in forty-three countries.

Summary for Patent: 6,008,228

Title: Pharmaceutical compositions containing proteinase inhibitors
Abstract:Compositions which increase the bioavailability of proteinase inhibitors are disclosed. Compositions which include a pharmaceutically acceptable carrier comprising monoglycerides of medium chain-fatty acids are preferred. Preferred medium chain fatty acid glycerides include monoglycerides of saturated C.sub.6 to C.sub.12 fatty acids, preferably C.sub.8 to C.sub.10 fatty acids The pharmaceutically acceptable carrier preferably has an acid value of less than or equal to about 2.5. Preferably, the ratio of monoglycerides of medium chain fatty acid to the proteinase inhibitor is about at least 1.5.
Inventor(s): Bailey; Carole Anne (Warren, NJ), Ferdinando; Josephine Christine (Chippenham, GB), Shah; Navnit (Clifton, NJ)
Assignee: Hoffman-La Roche Inc. (Nutley, NJ)
Application Number:08/616,233
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 22nd percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Hoffmann La Roche
FORTOVASE
saquinavir
CAPSULE;ORAL020828-001Nov 7, 1997DISCNNo6,008,228*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,008,228

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina002759► subscribe
Austria226075► subscribe
Australia6300496► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc